Cannabis Epidemiology: A Selective Review

Abstract

Background Globally, the most widely used set of compounds among the internationally regulated drugs is cannabis. Objective To review evidence from epidemiological research on cannabis, organized in relation to this field’s five main rubrics: quantity, location, causes, mechanisms, and prevention/control. Method The review covers a selection of evidence from standardized population surveys, official statistics, and governmental reports, as well as published articles and books identified via MEDLINE, Web of Science, and Google Scholar as of July 2016. Results In relation to quantity, an estimated 3% to 5% of the world population is thought to have tried a cannabis product, with at least one fairly recent use, mainly extra-medical and outside boundaries of prescribed use. Among cannabis users in the United States, roughly one in 7–8 has engaged in medical marijuana use. In relation to location, prevalence proportions reveal important variations across countries and between subgroups within countries. Regarding causes and mechanisms of starting to use cannabis, there is no compelling integrative and replicable conceptual model or theoretical formulation. Most studies of mechanisms have focused upon a ‘gateway sequence’ and person-to-person diffusion, with some recent work on disability-adjusted life years. A brief review of cannabis use consequences, as well as prevention and control strategies is also provided. Conclusion At present, we know much about the frequency and occurrence of cannabis use, with too little replicable definitive evidence with respect to the other main rubrics. Given a changing regulatory environment for cannabis products, new institutions such as an independent International Cannabis Products Safety Commission may be required to produce evidence required to weigh benefits versus costs. It is not clear that government sponsored research will be sufficient to meet consumer demand for balanced points of view and truly definitive evidence.

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center

“…This may be attributed to cultural norms affecting prescribing physicians (i.e., cannabis is more likely to be offered to men), or to higher rates of requests for or compliance with this therapy, though this was not directly explored in our study. In any case, these data are in line with the findings of other epidemiologic studies, in which males were shown to be more inclined to use cannabis as a recreational drug [23-25] . …”

Does Cannabis Intake Protect Against Non-alcoholic Fatty Liver Disease? A Two-Sample Mendelian Randomization Study

“…Currently, there are about 36.7 million active cannabis users in North America (Anthony et al, 2017). The legalization of cannabis in some states resulted in a gradual rise in the prevalence of cannabis use (Cerda et al, 2012).…”

Newly incident cannabis use in the United States, 2002–2011: a regional and state level benchmark

“…This study’s investigation of geographical variations in cannabis incidence rates creates ‘benchmark values’ and should provide a useful foundation for a future extension of this line of epidemiological research on ‘place’ as a potential determinant of starting to use cannabis products. In a recent literature review, Anthony, Lopez-Quintero & Alshaarawy (2017) noted a lack of survey-based incidence estimates for cannabis use around the globe (2017). This study illustrates such estimation of incidence rates using publicly available national data.…”